Loading…
Loading…
EPRXF (Eupraxia Pharmaceuticals Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
EPRXF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EPRXF and 80,000+ other tickers.
See exactly how EPRXF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EPRXF and 80,000+ other tickers.
Eupraxia Pharmaceuticals Inc. operates as a clinical-stage biotechnology firm, focusing its efforts on the discovery, advancement, and commercialization of innovative technologies within the biotech landscape. The company's leading therapeutic compound, EP-104IAR, is currently progressing through Phase II clinical trials. This candidate is designed to address pressing unmet medical needs and provide pain relief for individuals suffering from knee osteoarthritis. Additionally, its potential is being explored for the treatment of osteoarthritis in animal companions, specifically dogs and…
Shares of Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF - Get Free Report) traded up 3.6% during trading on Wednesday. The stock traded as high as C$8.47 and last traded at C$8.42. 105,192 shares traded hands during mid-day trading, an increase of 1,320% from the average session volume of 7,410 shares. The stock had previously closed at
Company's Listing Application Approved by Nasdaq VICTORIA, BC , April 3, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that the Company's common shares have been approved for listing on the Nasdaq Capital Market ("Nasdaq"). The Company's shares are expected to begin trading on Nasdaq on April 5, 2024, under the ticker symbol "EPRX".
VICTORIA, BC , April 1, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023. All amounts are expressed in U.S. dollars unless otherwise indicated.